Does the media refer more to CAPR or KYMR?

In the previous week, Capricor Therapeutics and Capricor Therapeutics both had 6 articles in the media. Kymera Therapeutics' average media sentiment score of 1.18 beat Capricor Therapeutics' score of 0.25 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SYRE or CAPR?

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics N/A N/A -$155.20M -$2.08 N/A Capricor Therapeutics N/A N/A -$105.04M -$2.32 N/A

Is SYRE or CAPR more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Capricor Therapeutics N/A -59.27% -48.65%

Does the media refer more to SYRE or CAPR?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Capricor Therapeutics. MarketBeat recorded 11 mentions for Spyre Therapeutics and 6 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 0.25 beat Spyre Therapeutics' score of 0.01 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CAPR or PTGX?

In the previous week, Capricor Therapeutics had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Capricor Therapeutics and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.64 beat Capricor Therapeutics' score of 0.25 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or CAPR?

In the previous week, Capricor Therapeutics had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Capricor Therapeutics and 2 mentions for Rhythm Pharmaceuticals. Capricor Therapeutics' average media sentiment score of 0.25 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer MIRM or CAPR?

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 6 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.37 beat Capricor Therapeutics' score of 0.25 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Capricor Therapeutics (CAPR) Competitors

$26.16 -0.55 (-2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$26.37 +0.21 (+0.82%)

As of 05:13 PM Eastern

Compare

CAPR vs. KYMR, SYRE, PTGX, RYTM, and MIRM

Should you buy Capricor Therapeutics stock or one of its competitors? MarketBeat compares Capricor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capricor Therapeutics include Kymera Therapeutics (KYMR), Spyre Therapeutics (SYRE), Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Capricor Therapeutics compare to Kymera Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Capricor Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Kymera Therapeutics	$51.48M	118.17	-$311.35M	-$3.57	N/A

Capricor Therapeutics currently has a consensus target price of $48.36, indicating a potential upside of 84.88%. Kymera Therapeutics has a consensus target price of $118.10, indicating a potential upside of 59.70%. Given Capricor Therapeutics' higher probable upside, research analysts clearly believe Capricor Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Capricor Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

In the previous week, Capricor Therapeutics and Capricor Therapeutics both had 6 articles in the media. Kymera Therapeutics' average media sentiment score of 1.18 beat Capricor Therapeutics' score of 0.25 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kymera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Summary

Kymera Therapeutics beats Capricor Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

Spyre Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Spyre Therapeutics currently has a consensus target price of $91.33, indicating a potential upside of 26.85%. Capricor Therapeutics has a consensus target price of $48.36, indicating a potential upside of 84.88%. Given Capricor Therapeutics' higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Spyre Therapeutics had 5 more articles in the media than Capricor Therapeutics. MarketBeat recorded 11 mentions for Spyre Therapeutics and 6 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 0.25 beat Spyre Therapeutics' score of 0.01 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Spyre Therapeutics' return on equity of -42.88% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Summary

Spyre Therapeutics beats Capricor Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Capricor Therapeutics compare to Protagonist Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Capricor Therapeutics presently has a consensus price target of $48.36, indicating a potential upside of 84.88%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential upside of 17.53%. Given Capricor Therapeutics' higher possible upside, research analysts clearly believe Capricor Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Capricor Therapeutics has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A
Protagonist Therapeutics	$74.06M	85.12	-$130.15M	-$1.81	N/A

In the previous week, Capricor Therapeutics had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for Capricor Therapeutics and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.64 beat Capricor Therapeutics' score of 0.25 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Capricor Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Capricor Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Capricor Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Capricor Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$217.17M	27.12	-$196.54M	-$3.13	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

In the previous week, Capricor Therapeutics had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Capricor Therapeutics and 2 mentions for Rhythm Pharmaceuticals. Capricor Therapeutics' average media sentiment score of 0.25 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

21.7% of Capricor Therapeutics shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Capricor Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Capricor Therapeutics' return on equity of -59.27% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Rhythm Pharmaceuticals currently has a consensus price target of $131.81, indicating a potential upside of 53.40%. Capricor Therapeutics has a consensus price target of $48.36, indicating a potential upside of 84.88%. Given Capricor Therapeutics' higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Summary

Capricor Therapeutics beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Capricor Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Capricor Therapeutics	N/A	-59.27%	-48.65%

21.7% of Capricor Therapeutics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	10.02	-$23.36M	-$13.61	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

In the previous week, Mirum Pharmaceuticals and Mirum Pharmaceuticals both had 6 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.37 beat Capricor Therapeutics' score of 0.25 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals presently has a consensus target price of $137.64, indicating a potential upside of 47.09%. Capricor Therapeutics has a consensus target price of $48.36, indicating a potential upside of 84.88%. Given Capricor Therapeutics' higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Mirum Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Capricor Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.51B	$8.28B	$6.43B	$12.05B
Dividend Yield	N/A	2.52%	2.67%	5.56%
P/E Ratio	-11.28	16.16	23.75	23.75
Price / Sales	N/A	6.48	479.79	84.65
Price / Cash	N/A	17.45	26.99	37.25
Price / Book	4.73	3.55	10.28	6.78
Net Income	-$105.04M	$225.32M	$3.57B	$337.51M
7 Day Performance	-8.31%	-1.06%	-1.43%	-2.72%
1 Month Performance	-13.89%	2.21%	3.28%	1.86%
1 Year Performance	83.84%	-3.10%	23.37%	26.60%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	2.5375 of 5 stars	$26.16 -2.1%	$48.36 +84.9%	+87.7%	$1.51B	N/A	N/A	101
KYMR Kymera Therapeutics	2.4828 of 5 stars	$80.77 +2.4%	$118.10 +46.2%	+55.7%	$6.49B	$39.21M	N/A	170	News Coverage Analyst Forecast
SYRE Spyre Therapeutics	2.4883 of 5 stars	$73.65 -0.5%	$90.25 +22.5%	+334.0%	$6.43B	N/A	N/A	73	Positive News
PTGX Protagonist Therapeutics	2.4663 of 5 stars	$99.98 +0.8%	$115.21 +15.2%	+79.1%	$6.38B	$74.06M	N/A	120
RYTM Rhythm Pharmaceuticals	2.177 of 5 stars	$89.82 +2.3%	$131.81 +46.8%	+26.9%	$6.02B	$217.17M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. KYMR, SYRE, PTGX, RYTM, and MIRM

How does Capricor Therapeutics compare to Kymera Therapeutics?

Summary

How does Capricor Therapeutics compare to Spyre Therapeutics?

Summary

How does Capricor Therapeutics compare to Protagonist Therapeutics?

Summary

How does Capricor Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Capricor Therapeutics compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. KYMR, SYRE, PTGX, RYTM, and MIRM

How does Capricor Therapeutics compare to Kymera Therapeutics?

Do insiders & institutionals hold more shares of CAPR or KYMR?

Which has higher earnings & valuation, CAPR or KYMR?

Do analysts rate CAPR or KYMR?

Which has more volatility & risk, CAPR or KYMR?

Does the media refer more to CAPR or KYMR?

Is CAPR or KYMR more profitable?

Summary

How does Capricor Therapeutics compare to Spyre Therapeutics?

Which has stronger valuation & earnings, SYRE or CAPR?

Which has more volatility and risk, SYRE or CAPR?

Do analysts rate SYRE or CAPR?

Does the media refer more to SYRE or CAPR?

Do institutionals and insiders hold more shares of SYRE or CAPR?

Is SYRE or CAPR more profitable?

Summary

How does Capricor Therapeutics compare to Protagonist Therapeutics?

Do analysts recommend CAPR or PTGX?

Which has stronger earnings & valuation, CAPR or PTGX?

Does the media refer more to CAPR or PTGX?

Do institutionals & insiders hold more shares of CAPR or PTGX?

Is CAPR or PTGX more profitable?

Which has more volatility and risk, CAPR or PTGX?

Summary

How does Capricor Therapeutics compare to Rhythm Pharmaceuticals?

Which has preferable earnings & valuation, RYTM or CAPR?

Does the media prefer RYTM or CAPR?

Do insiders and institutionals believe in RYTM or CAPR?

Is RYTM or CAPR more profitable?

Do analysts rate RYTM or CAPR?

Which has more volatility and risk, RYTM or CAPR?

Summary

How does Capricor Therapeutics compare to Mirum Pharmaceuticals?

Is MIRM or CAPR more profitable?

Do institutionals and insiders hold more shares of MIRM or CAPR?

Which has better earnings & valuation, MIRM or CAPR?

Does the media prefer MIRM or CAPR?

Do analysts prefer MIRM or CAPR?

Which has more risk & volatility, MIRM or CAPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools